Immunogenicity and pharmacokinetic studies of recombinant Factor VIII containing lipid cochleates

Replacement therapy using recombinant factor VIII (rFVIII) is currently the most common therapy for hemophilia A, a bleeding disorder caused by the deficiency of FVIII. However, 15–30% of patients develop inhibitory antibodies against administered rFVIII which complicates the therapy. Encapsulation...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Kosloski, Matthew P., Peng, Aaron, Varma, Prashant R., Fathallah, Anas M., Miclea, Razvan D., Mager, Donald E., Balu-Iyer, Sathy V.
Formato: Artigo
Idioma:Inglês
Publicado: 2010
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3068242/
https://ncbi.nlm.nih.gov/pubmed/21114461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10717544.2010.536269
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares